Compare AngloGold Ashanti Limited (AU) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Becton Dickinson and Co — how do they compare? AngloGold Ashanti Limited trades at $78.33 (market cap $40.62B), while Becton Dickinson and Co trades at $154.29 (market cap $41.51B). The key difference: AngloGold Ashanti Limited and Becton Dickinson and Co are close in size by market cap, and AngloGold Ashanti Limited pays the higher dividend (5.73%). Which is the better fit depends on your goals.
| AU | BDX | |
|---|---|---|
Market Cap | $40.62B | $41.51B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $185.39 |
52-Week Low | $46.25 | $135.49 |
Enterprise Value | $39.75B | $57.97B |
Dividend Yield | 5.73% | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $79.76, down 2.85% amid bearish technical signals. The stock shows strong fundamentals with 2025 revenue growth to $9.89B and net income of $2.64B, supported by a 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS versus $2.27 forecast. Analyst consensus remains positive with a $118.60 price target, though technical indicators show selling pressure with support at $77-79 levels.
The outlook remains favorable given robust cash flow growth and geographic diversification, but faces risks from gold price volatility and recent technical weakness. With 64% analyst buy ratings and significant upside to price targets, the stock presents value opportunity for patient investors despite near-term bearish momentum.
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
